We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
COVID‐19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments.
- Authors
Heffler, Enrico; Detoraki, Aikaterini; Contoli, Marco; Papi, Alberto; Paoletti, Giovanni; Malipiero, Giacomo; Brussino, Luisa; Crimi, Claudia; Morrone, Daniela; Padovani, Marianna; Guida, Giuseppe; Gerli, Alberto Giovanni; Centanni, Stefano; Senna, Gianenrico; Paggiaro, Pierluigi; Blasi, Francesco; Canonica, Giorgio Walter
- Abstract
All centres have been contacted and inquired to report confirmed or highly suspect cases of COVID-19 (ie, patients with symptoms, laboratory findings and lung imaging typical of COVID-19 but without access to nasopharyngeal or oropharyngeal swab specimens because of clinical contingencies/emergency) among their cohorts of severe asthma. The total number of patients with severe asthma for each single region is reported under the each region name gl Nine (34.6%) infected patients experienced worsening of asthma during the COVID-19 symptomatic period; four of them needed a short course of oral corticosteroids for controlling asthma exacerbation symptoms. This is in line with the under-reported asthma cases among patients with COVID-19 patients.3 The COVID-19 related mortality rate in our cohort of patients was 7.7%, lower than in the general population (14.5% in Italy1). Since the end of February 2020, Italy, first non-Asian Country, has reported an ever increasing number of COronaVIrus Disease 19 (COVID-19) patients, which has reached over 200 000 confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected subjects, resulting in more than 34 000 deaths (data updated to June 19th, 20201).
- Subjects
ITALY; TYPE 2 diabetes; COVID-19; SARS-CoV-2
- Publication
Allergy, 2021, Vol 76, Issue 3, p887
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.14532